News | October 11, 2021
Sai Life Sciences presents its midterm report
The company has enabled a transformation across three core areas with an investment target of US $ 150 million
The company has enabled a transformation across three core areas with an investment target of US $ 150 million
The rolling submission to the U.S. FDA will begin in the fourth quarter of this year
The company plans to expand its portfolio in regulated markets aggressively
The start-up claims in clinical trials over 90 % achieved type 2 diabetes reversal and 92 % eliminated all diabetes medication within 90 days of joining the twin service
Next-generation radiofrequency catheter offers first thermal ablation perforator treatment advancement in over 10 years
RT-PCR test detects and differentiates SARS-CoV-2, influenza A, influenza B and respiratory syncytial virus
The rates for over 400 procedures were revised
The initiative will create an integrated network of Critical Care Units (CCUs) across the Apollo Hospitals network but also in partnership with non-Apollo units in India and overseas
The filing includes data from PROVENT Phase III trial showing 77% reduction in risk of developing symptomatic Covid-19 with a long-acting antibody combination (non-vaccine)
More than 90,000 patients utilise the services daily
Subscribe To Our Newsletter & Stay Updated
